comparemela.com

Latest Breaking News On - Cybin inc stock exchange - Page 1 : comparemela.com

Cybin : C$70M in potential funding through a combination of the previously announced common share purchase agreement and current at-the-market equity program helps support upcoming clinical milestones - - Topline clinical data readouts expected in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 - Form 6-K

- C$70M in potential funding through a combination of the previously announced common share purchase agreement and current "at-the-market" equity program helps support upcoming. | June 8, 2023

United statesUnited kingdomGabriel fahelDoug drysdaleExchange commissionHealth canadaLincoln park capital fundClinical facilitator training programNeither the neo exchange incDrug administrationCybin incChief executive officerGeneralized anxietyFacilitator training programBody awareKeeping momentum

Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones

- Michael Palfreyman Ph.D. and Brett Greene, who joined Cybin as part of the acquisition of Adelia Therapeutics, move into advisory roles - - Alex Nivorozhkin Ph.D. continues as Chief Scientific. | June 5, 2023

United kingdomUnited statesDoug drysdaleBrett greeneExchange commissionHealth canadaCybin incAdelia therapeutics incDrug administrationAdelia therapeuticsChief rd officerChief innovations officerChief scientific officerChief executive officerClinical milestonesCybin inc stock exchange

Cybin to Present at the Jefferies Healthcare Conference

Cybin Inc. , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce. | June 1, 2023

New yorkUnited statesUnited kingdomDoug drysdaleCybin incChief executive officerJefferies healthcare conferenceNew york cityCybin inc stock exchangePress releaseO cybn ca23256x1006

Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund

- Share purchase agreement further strengthens Company’s position to deliver on value-driving clinical milestones - . | May 30, 2023

United kingdomUnited statesDoug drysdaleHealth canadaExchange commissionCybin incDrug administrationLincoln park capital fundChief executive officerUnited states securitiesMultijurisdictional disclosure systemBase prospectusCybin inc stock exchangePress releaseIlestones cybn ca23256x1006

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

- CYB004, a deuterated dimethyltryptamine molecule, has potential to overcome existing limitations of DMT and is protected by a composition of matter patent through 2041 – Parts A and B. | May 24, 2023

United statesUnited kingdomDoug drysdaleHealth canadaCentre for human drug researchDrug administrationCybin incExchange commissionGeneralized anxiety disorderChief executive officerMajor depressive disorderHuman drug researchMajor depressiveCybin inc stock exchangePress releaseNd cybn ca23256x1006

vimarsana © 2020. All Rights Reserved.